Clinical trials: Respiratory Physiological Phenomena
Lung Diseases, Interstitial
A Study to Test Different Imaging Techniques in Patients With Different Types of Interstitial Lung Disease
The main objectives of this imaging biomarker study are to assess the annual lung function change in patients with progressive fibrosing interstitial lung disease (PF-ILD) including idiopathic pulmonary fibrosis (IPF), with Usual…
- Trial name
- NCT05492994
- Testing
- Spirometry, Diffusing Capacity of the Lung for Carbon Monoxide (DLCO), Magnetic Resonance Imaging
- Where
- Germany
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control
The study compared the 24-hour spirometry profile of indacaterol with that of placebo and with tiotropium as an active control in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT00615459
- Testing
- Indacaterol, Tiotropium
- Where
- 20 sites in Australia, Germany and 5 more
- Volunteers
- 169 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The primary purpose of this study is to evaluate lung function and health related quality of life (HRQoL) after 84 days of treatment with a single inhaler triple therapy combination of FF/UMEC /VI [100/62.5/25 microgram (mcg)]…
- Trial name
- NCT03478696
- Testing
- budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI
- Where
- 57 sites in United States, Czechia and 1 more
- Volunteers
- 732 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
WearME-Pro Phase II: Remote Use Usability and Longitudinal Validation Study (Patch Form Factor).
This Phase II investigation evaluates the safety, usability, and clinical performance of the WearME-Pro patch system for remote monitoring of adults with COPD in a home-use environment.
- Trial name
- WearME-Pro (NCT07430605)
- Testing
- WearME-Pro Patch System, FDA-cleared handheld spirometer (reference comparator), Cardea SOLO ECG patch (optional subset; exploratory HR reference)
- Where
- 3 sites in United States
- Volunteers
- 82 people
- Sponsor
- LASARRUS Clinic and Research Center
Allergic Asthma
A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma
Study JSP-CP-012 is designed as a proof of concept, parallel-group, single dose, double blind, placebo-controlled study using an allergen challenge model.
- Trial name
- NCT06592768
- Testing
- Briquilimab
- Where
- 6 sites in Canada
- Volunteers
- 17 people
- Sponsor
- Jasper Therapeutics, Inc.
Asthma
A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
The purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed replacement propellant HFO compared with BDA delivered using the currently approved…
- Trial name
- NCT06502366
- Testing
- BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg
- Where
- 128 sites in United States, China and 4 more
- Volunteers
- 424 people
- Sponsor
- AstraZeneca
Idiopathic Pulmonary Fibrosis
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
This study is open to adults who are at least 40 years old and have idiopathic pulmonary fibrosis (IPF). People can participate in the study if they have a forced vital capacity (FVC) greater than or equal to 45% of the predicted…
- Trial name
- NCT07036523
- Testing
- BI 765423
- Where
- 46 sites in United States, Australia and 8 more
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disorder
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung function study with BFF MDI (320/9.6 μg and 160/9.6 μg) compared to FF MDI 9.6 μg, BD MDI 320 μg, and open-label Symbicort® TBH (200/6 μg)…
- Trial name
- telos (NCT02766608)
- Testing
- BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, FF MDI 9.6 μg
- Where
- 259 sites in United States, Canada and 6 more
- Volunteers
- 2,389 people
- Sponsor
- Pearl Therapeutics, Inc.
COPD, COPD Exacerbation
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.
- Trial name
- TRITON (NCT04320342)
- Testing
- Beclomethasone Dipropionate, Glycopyrronium Bromide, Formoterol Fumarate
- Where
- 436 sites in United States, Argentina and 8 more
- Volunteers
- 3,406 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD, Heterogeneous Emphysema
To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr Valves
To compare the clinical outcomes of Endoscopic Lung Volume Reduction (ELVR) using Pulmonx Zephyr Valves vs. Standard of Care (SoC) in the treatment of heterogeneous emphysema subjects in a controlled trial design setting.
- Trial name
- TRANSFORM (NCT02022683)
- Testing
- ELVR (Endoscopic Lung Volume Reduction) with Zephyr Valves
- Where
- 17 sites in Belgium, France and 4 more
- Volunteers
- 97 people
- Sponsor
- Pulmonx Corporation
Mild Persistent Asthma
Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)
The aim of this exploratory investigation is to evaluate if the Forced Expiratory Volume in the 1st second (FEV1) measurements, fractional exhaled nitric oxide (FENO) and Provocative Concentration 20 (PC20) after Adenosine…
- Trial name
- NCT01343745
- Testing
- BDP/formoterol
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Duchenne Muscular Dystrophy (DMD)
A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids
The purpose of the study is to assess the efficacy of idebenone in delaying the loss of respiratory function in patients with DMD receiving concomitant glucocorticoid steroids
- Trial name
- SIDEROS (NCT02814019)
- Testing
- Idebenone 150 mg film-coated tablets
- Where
- 63 sites in United States, Austria and 13 more
- Volunteers
- 255 people
- Sponsor
- Santhera Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.
This is a research study to evaluate the efficacy and safety of the investigational drug Mitiperstat (AZD4831) in adult patients with chronic obstructive pulmonary disease.
- Trial name
- CRESCENDO (NCT05492877)
- Testing
- Mitiperstat (AZD4831)
- Where
- 101 sites in United States, Argentina and 12 more
- Volunteers
- 381 people
- Sponsor
- AstraZeneca
Asthma, Asthma Attack
Evaluating Asthma Exacerbation-induced Changes in Lung Function With a Home-based Spirometer
The investigators will study the use of a home-based spirometer (Spirobank Smart spirometer) that connects to a smartphone app (VitalFlo) in teenagers with persistent asthma to determine if clinically significant changes in lung…
- Conditions
- Asthma, Asthma Attack, Asthma, Allergic
- Trial name
- NCT03705325
- Testing
- Spirobank Smart spirometer
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- VitalFlo Inc.
Chronic Obstructive Pulmonary Disease, Hyperinflation
A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
The purpose of the study is to evaluate the effect of BGF MDI compared with placebo MDI on cardiac and lung function when administered in participants diagnosed with COPD and hyperinflation.
- Trial name
- ORATOS (NCT07073950)
- Testing
- Budesonide/Glycopyrronium/Formoterol Fumarate, Metered dose inhaler
- Where
- 7 sites in Germany, United Kingdom
- Volunteers
- 56 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COPD is a progressive disease characterized by increasing obstruction to airflow and the progressive development of respiratory symptoms including chronic cough, increased sputum production, dyspnea and wheezing.
- Trial name
- NCT03474081
- Testing
- FF/UMEC/VI, Tiotropium, Albuterol/salbutamol
- Where
- 72 sites in United States, Poland and 1 more
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
COVID-19
Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19
Objective of the study: to investigate the effect of meglumine succinate solution on the dynamics of metabolic blood parameters and respiratory function of the lungs in intensive care patients with new coronavirus infection.
- Trial name
- CARECOVID (NCT05172180)
- Testing
- Reamberin, Ringer's solution
- Where
- Russia
- Volunteers
- 105 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Pulmonary Disease, Chronic Obstructive
Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease
Relatively little information is available about the effects of salmeterol/fluticasone combination and fluticasone alone in COPD patients with a partial reversible pulmonary obstruction.
- Trial name
- NCT00549146
- Testing
- fluticasone propionate/salmeterol 250/50 DISKUS combination product, fluticasone propionate DISKUS 500mcg
- Where
- 17 sites in Netherlands
- Volunteers
- 290 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).
- Trial name
- MODIFY (NCT07456033)
- Testing
- Depemokimab
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 456 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects
PF-03526299, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.
- Trial name
- NCT00877539
- Testing
- PF-03526299, Fluticasone propionate
- Where
- 2 sites in United Kingdom
- Volunteers
- 29 people
- Sponsor
- Pfizer